Adial Pharmaceuticals Inc Common Stock (ADIL)

About ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and oth…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

www.adialpharma.com/

Fundamentals

1-day range

$5.45$5.79

Market cap

$7.80M

P/E (trailing)

—

P/E (forward)

-0.75

EPS (trailing)

$-9.93

Dividend yield

—

Beta

-394.72

Avg. volume

418.6K

Forecasts

3 analyst ratings

Adial Pharmaceuticals Inc Common Stock Competitors

Chosen by industry and closest market cap.

• ADIL

  Adial Pharmaceuticals Inc Common Stock

  $5.6

  ▼ 1.41%
  Market cap $7.80MP/E —
  $1.31$249.81
• MTVA

  MetaVia Inc. Common Stock

  $1.71

  ▲ 3.01%
  Market cap $7.64MP/E —
  $0.9661$19.03
• APRE

  Aprea Therapeutics Inc. Common stock

  $0.8387

  ▼ 2.48%
  Market cap $7.40MP/E —
  $0.548$1.69
• SNGX

  Soligenix Inc. Common Stock

  $0.38

  ▲ 0.00%
  Market cap $8.22MP/E —
  $0.28$3.22
• APUS

  Apimeds Pharmaceuticals US Inc. Common Stock

  $3.87

  ▼ 1.28%
  Market cap $7.32MP/E —
  $3.39$403.1
• TRAW

  Traws Pharma Inc. Common Stock

  $0.59

  ▲ 0.00%
  Market cap $7.18MP/E —
  $0.4301$3.27
• CNSP

  CNS Pharmaceuticals Inc. Common Stock

  $5.52

  ▲ 0.11%
  Market cap $8.46MP/E —
  $1.9$10.59

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
  benzinga · 8/28/2026
• Adial Pharmaceuticals Files Prospectus Related To The Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders
  Benzinga · 8/28/2026
• 12 Health Care Stocks Moving In Monday's Intraday Session
  Benzinga · 8/24/2026
• These stocks are moving in today's pre-market session
  ChartMill · 8/17/2026
• 12 Health Care Stocks Moving In Monday's Pre-Market Session
  Benzinga · 8/17/2026
• Adial Pharmaceuticals Says As Of Aug 10, Anticipates Termination Of CEO Cary Claiborne After 2026 Annual Meeting; Anticipates Matthew Davidson To Be Appointed President And CEO; Anticipates Termination Of CFO Vinay Shah After 2026 Annual Meeting; Anticipates Board Changes And Legacy Member Resignations
  Benzinga · 8/13/2026

• Coastlands Capital LP · July 16, 2026 · Buy

  1.2K @ $2.75
• Coastlands Capital LP · July 14, 2026 · Buy

  2.0K @ $2.65
• Coastlands Capital LP · July 10, 2026 · Buy

  1.7K @ $2.7
• Coastlands Capital LP · July 9, 2026 · Buy

  10.1K @ $2.79
• Coastlands Capital LP · June 29, 2026 · Buy

  25.0K @ $2.6
• Matt Davidson · June 12, 2026 · Grant

  232.4K
• Young Wendy B. · June 12, 2026 · Buy

  36.4K @ $2.75
• Matt Davidson · June 11, 2026 · Grant

  101
• Matt Davidson · June 11, 2026 · Grant

  1.8K
• Matt Davidson · June 11, 2026 · Grant

  3.4K
• Matt Davidson · June 11, 2026 · Grant

  61.6K
• Anderson J. Kermit · April 7, 2026 · Grant

  9.2K
• Tony Goodman · April 7, 2026 · Grant

  26.5K
• Vinay Shah · April 7, 2026 · Grant

  17.3K
• Kevin Schuyler · April 7, 2026 · Grant

  9.2K

Institutional Ownership

March 31, 2026

Total shares held

29.7K

Total value held

$53.1K

Institutional holders

13